Direct effect of statins on homocysteine-induced endothelial adhesiveness: Potential impact to human atherosclerosis

European Journal of Clinical Investigation

Volumn 38, Issue 2, 2008, Pages 106-116

  Lin, C P ^a,d   Chen, Y H ^a,b   Lin, W T ^d   Leu, H B ^d   Liu, T Z ^c   Huang, S L ^a   Chen, J W ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cell adhesion molecules; Coronary artery disease; Endothelial adhesiveness; Homocysteine; Mononuclear cells; Statin

Indexed keywords

C REACTIVE PROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LUMINOL; MONOCLONAL ANTIBODY; PRAVASTATIN; SIMVASTATIN; SUPEROXIDE; VASCULAR CELL ADHESION MOLECULE 1;

AGED; AORTA; ARTICLE; ATHEROSCLEROSIS; CARDIAC PATIENT; CELL ADHESION; CELL ISOLATION; CELL PROTECTION; CELL STRAIN U937; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; HEART PROTECTION; HUMAN; HUMAN CELL; MALE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

AGED; ANTICHOLESTEREMIC AGENTS; CASE-CONTROL STUDIES; CELL ADHESION; CELL ADHESION MOLECULES; CORONARY ARTERY DISEASE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PRAVASTATIN; SIMVASTATIN;

EID: 38449120198     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01911.x     Document Type: Article

References (41)

1. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999 354: 407 13.
2. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997 337: 230 6.
3. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002 288: 973 9.
4. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006 354: 1578 88.
5. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004 291: 565 75.
6. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004 350: 2673 81.
7. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006 354: 1567 77.
8. Silverman MD, Tumuluri RJ, Davis M, Lopez G, Rosenbaum JT, Lelkes PI. Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. Arterioscler Thromb Vasc Biol 2002 22: 587 92.
9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360: 7 22.
10. Gotto Jr. AM Jr., Farmer JA. Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 2001 12: 391 4.
11. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001 21: 1712 9.
12. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 279: 1615 22.
13. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 335: 1001 9.
14. Morita H, Saito Y, Ohashi N, Yoshikawa M, Katoh M, Ashida T et al. Fluvastatin ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: the antioxidative properties of fluvastatin. Circ J 2005 69: 475 80.
15. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003 43: 825 30.
16. Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004 3: 101 11.
17. Ridker PM, Shih J, Cook TJ, Clearfield M, Downs JR, Pradhan AD et al. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 2002 105: 1776 9.
18. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000 20: 703 7.
19. Lin CP, Lin WT, Leu HB, Wu TC, Chen JW. Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. Int J Cardiol 2003 89: 53 62.
20. Leu HB, Lin CP, Lin WT, Wu TC, Lin SJ, Chen JW. Circulating mononuclear superoxide production and inflammatory markers for long-term prognosis in patients with cardiac syndrome X. Free Radic Biol Med 2006 40: 983 91.
21. Liuzzo G, Giubilato G, Pinnelli M. T cells and cytokines in atherogenesis. Lupus 2005 14: 732 5.
22. Chen JW, Chen YH, Lin SJ. Long-term exposure to oxidized low density lipoprotein enhances tumor necrosis factor-α-stimulated endothelial adhesiveness of monocytes by activating superoxide generation and redox-sensitive pathways. Free Radic Biol Med 2006 40: 817 26.
23. Roth J, Goebeler M, Ludwig S, Wagner L, Kilian K, Sorg C et al. Homocysteine inhibits tumor necrosis factor-induced activation of endothelium via modulation of nuclear factor-kappa b activity. Biochim Biophys Acta 2001 1540: 154 65.
24. Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006 41: 1031 40.
25. Zeng X, Dai J, Remick DG, Wang X. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ Res 2003 93: 311 20.
26. Alvarez-Maqueda M, El Bekay R, Monteseirin J, Alba G, Chacon P, Vega A et al. Homocysteine enhances superoxide anion release and NADPH oxidase assembly by human neutrophils. Effects on MAPK activation and neutrophil migration. Atherosclerosis 2004 172: 229 38.
27. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980 18: 113 21.
28. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993 91: 308 18.
29. Upchurch GR Jr., Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, Jr et al. Homocyst (e) ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997 272: 17012 7.
30. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD (P) H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003 23: 418 24.
31. McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr 2000 130: 369S 72S.
32. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000 279: F671 8.
33. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, Karmin O. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004 94: 28 36.
34. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats In vivo. Circ Res 1999 84: 409 16.
35. Koga T, Claycombe K, Meydani M. Homocysteine increases monocyte and T-cell adhesion to human aortic endothelial cells. Atherosclerosis 2002 161: 365 74.
36. Pruefer D, Scalia R, Lefer AM. Homocysteine provokes leukocyte- endothelium interaction by downregulation of nitric oxide. General Pharmacol 1999 33: 487 98.
37. Wang G, Woo CW, Sung FL, Siow YL, OK. Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules. Arterioscler Thromb Vasc Biol 2002 22: 1777 83.
38. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999 340: 115 26.
39. Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme a reductase in vascular endothelial cells: a mechanism for development of atherosclerosis? Circulation 2002 105: 1037 43.
40. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006 26: 2421 32.
41. Chen JW, Chen YH, Lin FY, Chen YL, Lin SJ. Ginkgo biloba extract inhibits tumor necrosis factor-alpha-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. Arterioscler Thromb Vasc Biol 2003 23: 1559 66.